GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuo Therapeutics Inc (OTCPK:AURX) » Definitions » Profitability Rank

Nuo Therapeutics (Nuo Therapeutics) Profitability Rank : 1 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Nuo Therapeutics Profitability Rank?

Nuo Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Nuo Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -330.96%. As of today, Nuo Therapeutics's Piotroski F-Score is 4.


Competitive Comparison of Nuo Therapeutics's Profitability Rank

For the Biotechnology subindustry, Nuo Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuo Therapeutics's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Nuo Therapeutics's Profitability Rank falls into.



Nuo Therapeutics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Nuo Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Nuo Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-0.652 / 0.197
=-330.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Nuo Therapeutics has an F-score of 4 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Nuo Therapeutics Profitability Rank Related Terms

Thank you for viewing the detailed overview of Nuo Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuo Therapeutics (Nuo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8285 El Rio, Suite 190, Houston, TX, USA, 77054
Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company's commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The company derives revenues from the sale of the Aurix product to customers consisting of primarily hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The Aurix product became commercially available for sale in current financial year.
Executives
Charles E Sheedy 10 percent owner TWO HOUSTON CENTER, SUITE 2907, HOUSTON TX 77010
David Emerson Jorden director, officer: CEO, CFO 2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381
Lawrence Atinsky director 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
C Eric Winzer director
Paul Mintz director C/O NUO THERAPEUTICS INC., 207A PERRY PARKWAY, SUITE 1, GAITHERSBURG MD 20877
Peter Clausen officer: CSO 11204 JEFFRO COURT, IJAMSVILLE MD 21754
Scott M. Pittman director 3683 JOHN NASH BLVD., BLUEFIELD WV 24701
Boyalife Investment Fund I, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Dean Tozer officer: CHIEF COMMERCIAL OFFICER C/O ADVANCED BIOHEALING, INC., 36 CHURCH LANE, WESTPORT CT 06880
Steven A Shallcross officer: SEE REMARKS C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Aldagen Holdings, Llc 10 percent owner, other: May be part of a 13(d) group C/O THOMAS A. ALLEN, ESQ., 4101 LAKE BOONE TRAIL, STE 300, RALEIGH NC 27607
Kathryne Carr 10 percent owner, other: May be part of a 13(d) group 315 OLD IVY WAY, SUITE 101, CHARLOTTESVILLE VA 22903
William W Brooke 10 percent owner, other: May be part of a 13(d) group 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Guercio Joseph Del director C/O CLARK INVESTMENTS, 7500 OLD GEORGETOWN ROAD, SUITE 620, BETHESDA MD 20814
B. Jefferson Clark 10 percent owner, other: May be part of a 13(d) group C/O ALDAGEN, INC., 2810 MERDIAN PARKWAY, SUITE 148, DURHAM NC 27713